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In the last half-century, human neuroscience methods provided a way to study schizo-
phrenia in vivo, and established that it is associated with subtle abnormalities in brain
structure and function. However, efforts to understand the neurobiological bases of the
clinical symptoms that the diagnosis is based on have been largely unsuccessful. In
this paper, we provide an overview of the conceptual and methodological obstacles that
undermine efforts to link the severity of speciﬁc symptoms to speciﬁc neurobiological
measures. These obstacles include small samples, questionable reliability and validity
of measurements, medication confounds, failure to distinguish state and trait effects,
correlation–causation ambiguity, and the absence of compelling animal models of spe-
ciﬁc symptoms to test mechanistic hypotheses derived from brain-symptom correlations.
We conclude with recommendations to promote progress in establishing brain-symptom
relationships.
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Advances in neurosciencemethods over the past 50 years have pro-
vided the means to study complex psychiatric disorders in vivo,
ﬁrmly establishing that disorders once viewed as psychological
reactions to stressful environments (particularly family environ-
ments) are associated with subtle abnormalities in brain structure
and function. This historical transition toward reconceptualiz-
ing psychiatric disorders as brain disorders is exempliﬁed by the
paradigm shift that gave primacy to neurobiological and neurode-
velopmental perspectives in understanding the etiopathology of
schizophrenia. Despite the clinical heterogeneity of schizophrenia,
a wide variety of neurobiological abnormalities have been repli-
cated across clinical samples and research laboratories, providing
some support for the neurobiological validity of the clinical crite-
ria used to diagnose patients. However, efforts to understand the
neurobiological bases of the clinical heterogeneity that schizophre-
nia comprises, mainly by correlating neurobiological measures
with speciﬁc symptoms, have been largely unsuccessful. Indeed,
it is fair to say that “inconsistency” has been the most consistent
ﬁnding to emerge from such efforts. In this paper, we provide an
overview of the myriad conceptual and methodological obstacles
that undermine efforts to link the severity of speciﬁc symptoms
to speciﬁc neurobiological measures, obstacles that ultimately
impede progress toward elucidating the neurobiological mech-
anisms underlying these symptoms. We conclude with recom-
mendations to promote progress in establishing brain-symptom
relationships.
THE OBSTACLES
SMALL SAMPLES
Neurobiological studies that compare schizophrenia patients to
healthy controls often include an analysis of symptom correlations
within the patient group. The sample sizes needed to detect mean
differences betweenpatients and controls are typically smaller than
the sample sizes needed to adequately power symptom correlation
studies. The common practice of exploring symptom correlations
within the relatively small patient samples employed in typical
case-control studies often results in failures to detect signiﬁcant
associations between neurobiological measures and severity rat-
ings of speciﬁc symptoms. However, in addition to insufﬁcient
power, correlations based on small sample sizes are also suscepti-
ble to spurious associations due to the inﬂuence that just a few data
points can have on the small sample correlation coefﬁcient. While
the magnitude of correlations in small samples can be surprisingly
large, leading some investigators to assume that the correlation is
unlikely to have arisen by chance alone, 95% conﬁdence intervals
estimated for small sample correlations are verywide, reﬂecting the
high level of uncertainty about where the true correlation actually
lies (Figure 1).
The problem of small samples is exacerbated by the need to
control the type-I error rate for the number of correlations tested,
leading to very stringent signiﬁcance thresholds. However, it is
not uncommon for studies that report symptom correlations to
forego correction for multiple tests by describing the correlational
analyses as “exploratory.” The result is that the schizophrenia
research literature is replete with inconsistent ﬁndings of “sig-
niﬁcant” correlations with various symptom dimensions based
on small patients samples. It is unclear whether these small sam-
ple correlations actually move the ﬁeld forward, or whether they
primarily clutter the literature with spurious ﬁndings.
What constitutes a small sample? Certainly sample sizes of
30 or less seem small given the need to represent the full range
of symptom variation in the patient sample. Sample sizes of
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FIGURE 1 |This figure shows the 95% confidence intervals for two
Pearson product-moment correlation coefficient values, r =0.25 and
r =0.75, as a function of sample size. Note the wide conﬁdence intervals
when correlations are based on small sample sizes, particularly when
n<50 subjects.
at least 50 patients seem better suited for robust detection of
symptom correlations, but such sample sizes are uncommon
for neurobiological studies of schizophrenia from individual
laboratories.
QUESTIONABLE RELIABILITY AND VALIDITY OF MEASUREMENTS
Implicit in the assessment of correlations between clinical symp-
tom measures and neurobiological measures is the assumption
that both measures possess sufﬁcient reliability and validity to
support a meaningful examination of their inter-relationship.
However, this assumption is seldom veriﬁed empirically. On the
clinical side, symptoms are typically quantiﬁed using interview-
based rating scales such as the Positive and Negative Symptom
Scale (PANSS; Kay et al., 1987), Scale for theAssessment of Positive
Symptoms (SAPS; Andreasen, 1984), Scale for the Assessment of
Negative Symptoms (SANS;Andreasen, 1983), or Brief Psychiatric
Rating Scale (BPRS;Overall andGorham,1962,1988). These scales
assess the severity of a speciﬁc symptom domain with a single item
or a few items, failing to adhere to the psychometric principle that
averaging over many items enhances the reliability of psychologi-
cal construct measurement (Wiggins, 1980; Anastasi, 1982). This
sharply contrasts with the typical multi-item approach to mea-
surement taken by psychologists when developing instruments
to assess cognitive abilities, personality traits, or other complex
psychological constructs.
The problem of unreliability of clinical symptom measure-
ments is exacerbated by the fact that symptoms are typically
assessed by interviewers making severity ratings based on semi-
structured patient interviews.While this calls for considerable skill
and judgment on the part of the interviewer, inter-rater reliability
is seldom assessed and reported in papers that examine symptom
correlations with neurobiological measures. Moreover, although
averaging the judgments of multiple raters together can enhance
the reliability of measurement, relative to the use of ratings from a
single rater (Wiggins, 1980; Anastasi, 1982), this approach is rarely
used in schizophrenia research. Even when inter-rater reliability is
assessed and reported in clinical studies, it is typically assessed by
having two or more raters rate the same set of patient interviews,
often derived from a videotape library of prior interviews. This
approach inﬂates the true reliability of interview-based ratings by
failing to consider the unreliability introduced by variation across
interviewers in their skill and technique in eliciting symptom
information from patients. Whether the ratings from two inde-
pendent raters conducting separate patient interviews are reliable
is typically not examined in schizophrenia studies, obscuring what
may be a major source of measurement error in the assessment of
symptom severity.
In addition to the variation introducedbydifferent interviewers
conducting clinical ratings, unreliability also arises from inconsis-
tencies in thewaypatients endorse anddescribe speciﬁc symptoms,
which may interact with the speciﬁc interviewer but also with
the particular mental state of the patient. Again, the degree to
which the reliability of symptom ratings is degraded by patient
inconsistencies in reporting is seldom quantiﬁed in schizophre-
nia studies, leading to inﬂated estimates of the true reliability of
symptom ratings. The need for reliable symptom measurements
when correlating symptom ratings with neurobiological measures
is underscored by the well-known principle that reliability sets
the upper limit on validity; that is, assuming that measurement
errors are random,a clinical symptommeasure cannot be expected
to correlate more highly with a neurobiological measure than
it correlates with itself (Wiggins, 1980; Anastasi, 1982; de Klerk,
2008).
Aside from reliability concerns in connection with interview-
based symptom rating scales, there is good reason to question
whether these ratings are valid reﬂections of the speciﬁc symp-
tom severities they are intended to capture. There are a number
of threats to validity of clinical ratings that are seldom discussed
in the schizophrenia research literature. For example, schizophre-
nia patients may have difﬁculty providing accurate information
about their symptoms, including their frequency, duration, sever-
ity, and impact on their lives. These difﬁculties may arise from
a lack of insight, deﬁcits in self-reﬂection and self-monitoring,
poor memory when trying to recount the frequency and sever-
ity of symptoms that have occurred over prior weeks or months,
guardedness and paranoia leading to under-reporting of symp-
toms, and desire to please the interviewer leading to over- or
under-reporting of symptoms. While alternatives to interview-
based retrospective self-reports of symptoms have been described
in the literature, including experience sampling methods (Csik-
szentmihalyi and Larson, 1987; Ben-Zeev et al., 2011; Swendsen
et al., 2011; Oorschot et al., 2012) where patients report symptoms
in real-time in response to a randomly delivered signal (e.g., pager
or phone call) or record symptoms in a diary on a daily basis, these
approaches are seldom used in neurobiological studies of schiz-
ophrenia. Undoubtedly, such measurements are time consuming
and challenging to obtain, but they may provide a more valid pic-
ture of the severity of speciﬁc symptoms over a deﬁned timeperiod
than can be obtained from retrospective reports elicited during an
interview.
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Of course, the same concerns about measurement reliability
and validity apply to the neurobiological measurements that are
correlated with symptom measures in schizophrenia studies. Typi-
cally there is no attempt to establish that neurobiological measures
derived from neuroimaging or electrophysiological recordings are
reliable over time. Yet, this is often an implicit assumption when
correlating such measures with ratings that retrospectively inte-
grate symptom severity information over the past week, the past
month, or the patient’s lifetime. Unreliability of neurobiological
measures over relatively short time periods can be expected to
attenuate the observed correlations between these measures and
symptom severity ratings.
MEDICATION AND TREATMENT RESPONSE CONFOUNDS CLINICAL
SEVERITY RATINGS
Medication status is another factor that introduces noise into the
assessment of correlations between symptom severity and neu-
robiological measures. In most neurobiological studies of schizo-
phrenia, patients are taking stable doses of anti-psychotic med-
ication (and other medications such as antidepressants, mood
stabilizers, and anxiolytics) at the time of testing. As a result,
ratings of symptom severity reﬂect variation across patients in
the responsiveness of symptoms to treatment, rather than just
the variation across patients in the primary pathophysiological
processes underlying the severity of speciﬁc symptoms. Thus, tak-
ing auditory hallucinations as an example, it may be that the
neurobiological abnormalities underlying auditory hallucinations
will correlate with the severity of untreated hallucinations but not
with the severity of residual hallucinations present during chronic
anti-psychotic treatment.
In addition, to the extent that patients with more severe or
treatment-resistant symptoms receive higher doses of medica-
tion, dose-related medication effects can confound the corre-
lation between a neurobiological measure and symptom rat-
ings, potentially introducing spurious correlations between them.
While the confounding effects of medication and variation in
treatment response can be addressed by studying unmedicated
patients, it is generally considered unethical to subject patients
to a drug washout solely for the purpose of studying them in an
unmedicated state in neurobiological research protocols.
STATE VS. TRAIT CONFUSION
The natural history of schizophrenia involves ﬂuctuations in the
severity of symptoms, particularly positive symptoms, over the
illness course. While these ﬂuctuations can be inﬂuenced by envi-
ronmental stressors, they may also be due to pathophysiological
ﬂuctuations that have yet to be elucidated. In any case, patients
also exhibit trait-like individual differences in symptom severity,
with some patients having milder forms of the illness and oth-
ers being more severely affected. Clinical state ﬂuctuations over
time are superimposed on these trait-like individual differences,
with each patient ﬂuctuating around his or her own mean level of
severity for any given symptom.
Some neurobiological measures, particularly those that reﬂect
brain function and potentially the dynamic neural mechanisms
underlying speciﬁc symptoms (e.g., ERP or fMRI activation mea-
sures), are also likely to show trait-like individual differences and
state-related ﬂuctuations over time around each patient’s own
mean for that measure. In cross-sectional studies that attempt
to correlate neurobiological measures with symptom ratings, the
trait- and state-related contributions to a patient’s symptom
severity and neurobiological function are confounded, poten-
tially obscuring a true correlation between state-related changes
in symptom severity and neurobiological function. Detection of
such correlations requires multi-wave longitudinal assessments in
order to model the covariation between a neurobiological measure
and symptom severity within each subject without the confound
of trait-like individual differences. We successfully demonstrated
such an approach in a study that showed ﬂuctuations in the P300
component of the auditory ERP to correlate with positive symp-
tom ﬂuctuations within patients over time (Mathalon et al., 2000).
This relationship was not evident in a cross-sectional analysis that
attempted to correlate the between-subject differences in P300 and
positive symptom severity at a single time point.
Other neurobiological measures that reﬂect more static char-
acteristics of the brain may not be sensitive to clinical state ﬂuc-
tuations but rather may underlie trait-like individual differences
between patients in symptom severity. For example, allelic varia-
tion in particular genesmay be correlatedwith trait-like individual
differences in the propensity to hallucinate or with themean sever-
ity of hallucinations over the illness course. Such correlations
may be signiﬁcantly attenuated in cross-sectional study designs
because the symptom ratings are excessively inﬂuenced by the
patient’s current clinical state. Yet the correlation may become
evident if symptom ratings are averaged over multiple occasions
over the illness course in order to increase their sensitivity to trait-
like individual differences. Averaging over multiple measurement
occasions increases the temporal reliability of a symptom mea-
sure as predicted by the well-known Spearman–Brown prophecy
formula from classical test theory. In practice, the beneﬁt of this
approach was demonstrated by Epstein and colleagues in connec-
tion with the validation of personality trait measures as predictors
of speciﬁc behaviors (Epstein, 1984, 1997; Epstein and O’Brien,
1985; Epstein et al., 1996). We similarly showed enhanced detec-
tion of the correlation between negative symptoms and P300
amplitude by averaging each of the measures over multiple mea-
surement occasions over the illness course (Mathalon et al., 2000).
Similarly, we demonstrated enhanced detection of correlations
between progressive gray matter decline in schizophrenia and pos-
itive symptom severity by averaging the symptom severity over
the baseline and follow-up assessments (Mathalon et al., 2001). In
general, studies that examine symptom correlations with neuro-
biological measures in the schizophrenia literature do not make
explicit whether the neurobiological measures posited to under-
lie speciﬁc symptoms should show state-related, or trait-related,
covariation with symptom severity. The failure to make this dis-
tinction leads to sub-optimal study designs for testing hypotheses
about brain-symptom relationships.
CORRELATION–CAUSATION LIMITATIONS
A signiﬁcant limitation of clinical research in general, and schiz-
ophrenia research in particular, is that we are generally lim-
ited to studying pre-existing symptoms and brain abnormalities.
Our inability to experimentally manipulate brain mechanisms to
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modulate speciﬁc symptoms leads us to rely exclusively on corre-
lational data to evaluate mechanistic models of speciﬁc symptoms.
Since correlations cannot prove causation, even the demonstration
of robust and replicable correlations between a neurobiological
measure and symptom severity cannot deﬁnitively establish that
there is a causal relationship.
THIRD VARIABLES
Related to the correlation–causation limitation of clinical research
studies is the potential for correlations between speciﬁc neuro-
biological measures and speciﬁc symptoms to be mediated by
“third variables.” Often these third variables are not measured
in the study, obscuring their role in producing the observed
brain-symptom correlation. Examples may include exposures to
environmental toxins, abnormalities of speciﬁc peptides or pro-
teins, or other pathophysiological mechanisms that have yet to be
elucidated. Such variables may give rise to both the measured neu-
robiological abnormality and the clinical symptom being assessed,
and the resulting correlation between the two may have little to do
with any underlying causal relationship between them. Moreover,
to the extent that the severity of apparently distinct symptoms such
as hallucinations and persecutory delusions are correlated, the
apparent relationship between a neurobiological measure and one
symptom (e.g., hallucinations)may bemediated by its relationship
with the correlated symptom (e.g., delusions). Indeed, it remains
likely that the actual causal pathophysiological mechanisms that
give rise to a number of measured neurobiological abnormalities
and a wide range of clinical symptoms, as well as observed cor-
relations between them, have yet to be discovered. This problem
fundamentally limits the ability of correlations between neurobio-
logical measures and symptom severity to deﬁnitively identify the
neurobiological causes of speciﬁc symptoms in schizophrenia.
MISTAKEN A PRIORI HYPOTHESES
A minority of clinical symptom correlation studies in schizo-
phrenia are motivated by speciﬁc mechanistic hypotheses about
how abnormalities of a speciﬁc neurobiological measure should
be selectively related to speciﬁc symptoms. While hypothesis dri-
ven analyses are generally considered to have more scientiﬁc value
than exploratory “ﬁshing expeditions,” conceptually reasonable
hypotheses may nonetheless be incorrect. There are numerous
examples of this in the schizophrenia literature. Working mem-
ory deﬁcits, which compromise the ability to hold information
online for short periods of time, have been hypothesized to con-
tribute to formal thought disorder (i.e., disorganized thought
process) in schizophrenia (Goldman-Rakic, 1994, 1999), yet rela-
tionships between them have not generally been found (but see
Perlstein et al., 2001). Similarly, abnormalities in semantic net-
work activations, as reﬂected by the N400 ERP component, might
reasonably be predicted to underlie formal thought disorder, yet
often it is delusional thinking rather than thought disorder that
correlates with N400 (Debruille et al., 2007). The error-related
negativity (ERN), an ERP component elicited by commission
errors in choice-response tasks, has been linked to reward process-
ing and reward prediction errors (Goldman-Rakic, 1999; Holroyd
and Coles, 2002). Based on this, it is reasonable to predict that
ERN abnormalities in schizophrenia should be related to negative
symptoms, particularly motivational impairments and anhedonia
(Morris et al., 2011).However, reducedERNamplitude has instead
generally been associatedwith increasedpositive symptomseverity
(Mathalon et al., 2002) or the paranoid subtype of schizophrenia in
several studies (Kopp and Rist, 1999; Mathalon et al., 2002). Thus,
sometimes a priori theoretical models may lead investigators to
make the wrong prediction about which symptoms will corre-
late with a neurobiological measure. While this argues in favor of
data-driven exploratory analyses of brain-symptom correlations,
the down side of such explorations is the inﬂated type-I error rate
associated with statistical testing of large numbers of correlations.
ABSENCE OF COMPELLING ANIMAL MODELS FOR SPECIFIC
SYMPTOMS
A potentially powerful approach to corroborating speciﬁc symp-
tom correlations with neurobiological measures from a mechanis-
tic perspective is to experimentallymanipulate the neurobiological
measure to induce the symptom in an animal model. Unfortu-
nately, despite the fact that some investigators have speculated that
psychotic like symptoms can be observed in non-human primates,
there are no compelling animal models for the cardinal symptoms
of schizophrenia including auditory hallucinations, delusions, for-
mal thought disorder, and negative symptoms. Relative to other
medical diseases that have animalmodels (e.g.,diabetes), the schiz-
ophrenia ﬁeld is hampered by the fact that the symptoms are
mainly evident via self-report and language-based communica-
tion, neither of which are readily studied in non-human primates
or rodents. This fundamentally limits our ability to get scientiﬁc
traction on the problem of elucidating the neurobiological basis of
speciﬁc symptoms in schizophrenia. It should be noted that animal
models have been developed to study neurobiological measures
known to be abnormal in patients in schizophrenia, including
ERP components such as mismatch negativity (Javitt et al., 1996;
Ehrlichman et al., 2009; Amann et al., 2010) and P50 sensory gat-
ing (Freedman et al., 1996; Metzger et al., 2007; Amann et al.,
2010). However, these approaches do not overcome the challenges
of establishing homologies between animal models and speciﬁc
clinical symptoms.
POTENTIAL SOLUTIONS AND RECOMMENDATIONS
LARGER SAMPLES AND BETTER MEASUREMENTS
Efforts to ﬁnd robust correlations between speciﬁc symptoms and
speciﬁc neurobiological measures in schizophrenia would likely
achieve more success if such studies employed larger sample sizes
where conﬁdence intervals are tighter and spurious correlations
are less likely. Inspection of the conﬁdence interval plots shown in
Figure 1 suggest that the beneﬁts of larger samples for detecting
correlations with conﬁdence starts to diminish after somewhere
between 50 and 100 subjects (see Figure 1). In addition, the ﬁeld
needs to make advances in the measurement of symptoms, going
beyond the retrospective interview-based ratings of one or a few
items that typify the approach taken in current studies. Examples
of such approaches include multi-item ratings scales for halluci-
nations like the psychotic symptom rating scale (PSYRATS; Drake
et al., 2007), real-time event sampling to reduce the reliance on
patient’s retrospective accounts of their symptoms, and assess-
ments of symptoms at multiple time points over the illness course
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to facilitate the distinction between trait- and state-related vari-
ation in symptom severity. Finally, greater emphasis needs to be
placed on accurate estimation of the reliability of symptom mea-
surements, aswell as the reliability of the neurobiologicalmeasures
that are correlated with symptom severity.
STUDIES OF FIRST-EPISODE MEDICATION-NAIVE PATIENTS AND
CHRONIC PATIENTS WHO DO NOT ADHERE TO MEDICATION REGIMENS
Studies of medication naïve ﬁrst-episode patients is a potentially
useful strategy for capturing variation in primary symptom sever-
ity with the confounding effects of medication, but such patients
are difﬁcult to recruit and the duration of time that medication
can be ethically withheld is fairly limited. Moreover, to the extent
that schizophrenia involves a progressive pathophysiology over the
illness course, symptom correlations present at the onset of illness
may not hold for chronic patients. That symptoms may depend
on the stage of illness is supported by studies that suggest that pos-
itive symptoms become less severe and negative symptoms more
prominent in the later stages of schizophrenia (McGlashan, 1988;
McGlashan and Fenton, 1992).
In addition, studying samples of schizophrenia patients who
have transiently discontinued their medication or who choose not
to take medication is another approach to capturing symptom
variation in the absence of medication confounds. However, this
approach may not yield symptom correlations that generalize to
the entire population of schizophrenia patients, particularly to
the extent that chronic patients who can live independently in
the community without medication may not be representative of
schizophrenia patients in general.
OVERCOMING THE CORRELATION–CAUSATION LIMITATION OF
CLINICAL RESEARCH STUDIES
One strategy that attempts to overcome the limitations of cor-
relational brain-symptom data in clinical research studies is to
use pharmacological challenges with agents that affect speciﬁc
neuroreceptors in order to transiently exacerbate symptoms in
patients, or to transiently induce schizophrenia-like symptoms
in healthy volunteers. This strategy is exempliﬁed by the use of
the NMDA-receptor antagonist, ketamine, in challenge studies
with patients (Lahti et al., 1995) and healthy volunteers (Krystal
et al., 1994, 2003; Adler et al., 1999; Umbricht et al., 2000; Moore
et al., 2011; Neill et al., 2011), to test the hypothesis that NMDA-
receptor hypofunction contributes to both clinical symptoms and
neurocognitive deﬁcits in schizophrenia.
Another promising approach to overcoming the correlation–
causation conundrum that is still in its early stages of development
is the use of transcranial magnetic stimulation (TMS) to tran-
siently perturb speciﬁc brain regions and circuits (Slotema et al.,
2010). While repetitive TMS has already been studied as a poten-
tial treatment for auditory hallucinations (Hoffman et al., 2000),
the possibility of using TMS targeted at speciﬁc brain regions
to transiently increase or decrease speciﬁc symptoms in order to
provide evidence for the causal role of that brain region in pro-
ducing or modulating the symptom remains largely unexplored.
Nonetheless, both the pharmacological probe and the TMS probe
approach to establishing causal connections between brain func-
tion and speciﬁc symptoms have some conceptual limitations. In
particular, even if manipulating brain function with these meth-
ods can reproduce schizophrenia-like symptoms, this does not
preclude the possibility that distinctly different pathophysiological
mechanisms give rise to these symptoms in schizophrenia.
EXTENDING SYMPTOM DIMENSIONS ACROSS TRADITIONAL
DIAGNOSTIC BOUNDARIES
To the extent that some symptoms of schizophrenia are also
evident in other neuropsychiatric disorders, studying these symp-
toms across disorders can provide some leverage against con-
founds that tend to be more speciﬁc to the schizophrenia spec-
trum. For example, auditory hallucinations can occur in bipolar
mania or depression when psychosis accompanies these mood
states. Bipolar patients may not have the chronic exposure to
anti-psychotic medication typical of schizophrenia, instead being
treated with drugs like lithium, valproic acid, and antidepres-
sants. This provides some opportunities to examine symptom
correlations with neurobiological measures in bipolar disorder
without the confound of dopamine D2 blockade associated with
anti-psychotic drugs. Moreover, bipolar patients do not tend to
exhibit the negative symptoms or severe functional impairment
characteristic of schizophrenia, allowing further dissociation of
what tend to be correlated impairments in schizophrenia. Indeed,
linking symptoms to brain circuits across traditional diagnostic
boundaries has been identiﬁed as a major research initiative by
NIMH, the so-called Research Domain Criteria (RDoC) initia-
tive. This approach may provide a greater range of variability
for speciﬁc symptoms and neurobiological abnormalities that can
enhance the likelihood of ﬁnding signiﬁcant covariation between
them.
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